Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Test Reveals Extent of Brain Damage

By LabMedica International staff writers
Posted on 27 Mar 2013
An immunoassay has been used to assess the extent of brain damage following head injuries or concussion in sportsmen involved in contact sports. More...


The enzyme-linked immunosorbent assay (ELISA) measured the levels of the astrocytic protein S100B which is normally only found in the brain, but leakage into the blood indicates blood-brain barrier disruption (BBBD) which may cause an immune response associated with production of autoantibodies.

Scientists at the Cleveland Clinic (Cleveland, OH, USA) and the University of Rochester (NY, USA) enrolled 67 volunteers from three American college football teams and collected blood samples before and after matches. The serum levels of S100B and autoantibodies against S100B were measured and correlated by direct and reverse immunoassays. Computerized cognitive testing, diffusion tensor imaging, and an estimation of head hits were also carried out.


The S100B measurements were performed using an ELISA kit (Diasorin; Saluggia, Italy) and reading carried out on a multiplate fluorescent reader. Fluorescent signals were converted into ng/mL as per standard curve concentrations. Serum S100B autoantibody measurements were optimized using a monoclonal antibody (Meridian Life Science Inc.; Cincinnati, OH, USA) in an ELISA system and read on a plate reader at 490 nm.


The investigators found elevations of serum S100B indicating blood-brain barrier disruption occur in football players who experience subconcussive head hits (SHH) below the threshold for a diagnosis of concussion. They also showed that players who during a season experience the most significant repeated elevations of S100B are also those with the highest titer of serum S100B autoantibodies. Out of the 27 players who had preseason S100b blood levels measured, four showed signs of an autoimmune response to the protein. Brain tissue damage was confirmed in the players through a series of brain scans.


Damir Janigro, PhD, the senior author of the study said, "Think of the blood-brain barrier disruption as opening a door to the brain that should not be open. Proteins like S100B, which normally stay inside the brain, get out where they are not supposed to be and get attacked. In addition, the door is open for things that do not belong in the brain to get in." The blood test is a great deal less expensive at around USD 40 than other means of evaluating the extent of head trauma, such as computed axial tomography (CAT) scans. The study was published on March 6, 2013, in the journal Public Library of Science ONE (PLOS ONE).

Related Links:

Cleveland Clinic
University of Rochester
Diasorin



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Pipette
Accumax Smart Series
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.